Navigation Links
A protein sequence associated with Huntington’s disease may become life-saving vaccine component

On June 10, 2008 the scientific journal "Vaccine" published a paper by the Massachusetts based biotech company Cure Lab, Inc., demonstrating that a protein sequence important in neurodegenerative Huntington's disease can be safely used as a new generation of vaccine adjuvants.

The major component of every vaccine is an antigen that elicits specific immunity to a particular virus, bacteria or even cancer cells. Search for better antigens is one of the most pressing medical and public health necessities, and the biotech industry invests heavily in this research. However, antigens are able to generate a limited immune response if administered alone. In order to be protective or therapeutic, vaccine compositions have to be supplemented with adjuvants, strong facilitators of the immune response. In the search for efficient adjuvants that are also non-toxic, scientists at Cure Lab, Inc. discovered a novel paradigm that capitalizes on insights from recent breakthroughs in understanding the fatal neurodegenerative disorder, Huntington's.

Huntington's disease results from mutations in the protein huntingtin, which contains a sequence of polyglutamine residues (polyQ). In healthy individuals, huntingtin contains less than 35 glutamines in the polyQ segment. However, in neurons of Huntington's patients, the number of glutamine residues in the sequence expands to more than 36. This induces protein self-aggregation, or formation of big protein "chunks", and eventually causes neuronal dysfunction. Recent research findings indicate that attachment of a prolonged polyQ segment to almost any protein promotes its aggregation.

"There were two ideas - said Alex Shneider, Cure Lab's founder and CEO- which stimulated us to test if attachment of a long polyQ "tail" to an antigen can enhance immune response to vaccination". First, he noticed that small aggregates formed by an antigen fused to a polyQ tail resembled the droplets that conventional adjuvants formed with antigenic peptides exposed on their surface. Dr. Shneider hypothesized that these polyQ containing aggregates were easily taken up by antigen-presenting cells, as is the case with adjuvant droplets, triggering the immune response.

Another hypothesis was proposed by Michael Sherman, professor at Boston University Medical School and scientific consultant at Cure Lab. "We knew- said Michael Sherman- that polyQ aggregates are destroyed in cells by a special degradation system, called autophagy. Interestingly, autophagy plays a key role in the processing of certain antigens, which is critical for the immune response. So, attachment of a polyQ tail should specifically target the antigen to autophagy, which in turn should facilitate the response. Thus, polyQ would serve as a molecular adjuvant".

There are two branches to the immune system. One is responsible for developing antibodies against bacteria, viruses and toxins freely circulating in the organism. Another is aimed at eliminating virus-infected or cancer cells. Cure Lab's paper demonstrates that the new polyQ-based adjuvant efficiently enhances both branches of the immune response to a poor model antigen. Importantly, the adjuvant caused no apparent toxicity in mice.

Many questions remain to be answered. The adjuvant properties of the polyQ tail will have to be tested for each individual antigen of medical and veterinary importance. However, this work may launch a new era in vaccine development, the era of molecular adjuvants.


Contact: Alex Shneider
Cure Lab, Inc.

Related biology news :

1. Fruit fly helps identify protein critical to eggshell formation that may be pesticide target
2. Protein fibrils as alternative plastics?
3. Montana State University researchers map iron transport protein
4. Plant biologists discover unexpected proteins affecting small RNAs
5. New clues to how proteins dissolve and crystallize
6. Ancient protein offers clues to killer condition
7. New discovery on role of vital protein that fights meningitis
8. Researchers report the cloning of a key group of human genes, the protein kinases
9. Genetic sequencing of protein from T. rex bone confirms dinosaurs link to birds
10. Proteins that stop a major signaling pathway can also generate new proteins
11. Researchers reveal structure of protein that repairs damage to cancer cells
Post Your Comments:
(Date:5/24/2016)... superior patient care by providing unparalleled technology to leaders of the medical imaging industry. ... recently added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and ... clinical trial team. , Using the CONSULT module, patients and physicians can schedule a ...
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks ... to industrial engineering, was today awarded as one ... selection of the world,s most innovative companies. Ginkgo ... scale for the real world in the nutrition, ... engineers work directly with customers including Fortune 500 ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Researchers at the ... commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject ... it now. , Diagnostic biomarkers are signposts in the blood, lung fluid or ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology: